Nektar Therapeutics (NASDAQ:NKTR) COO John Nicholson sold 4,077 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $31.37, for a total value of $127,895.49. Following the completion of the sale, the chief operating officer now directly owns 166,578 shares of the company’s stock, valued at $5,225,551.86. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
John Nicholson also recently made the following trade(s):
- On Tuesday, February 19th, John Nicholson sold 3,822 shares of Nektar Therapeutics stock. The shares were sold at an average price of $42.39, for a total value of $162,014.58.
Nektar Therapeutics stock traded up $0.68 during mid-day trading on Friday, reaching $32.02. 1,705,490 shares of the company were exchanged, compared to its average volume of 1,645,948. Nektar Therapeutics has a twelve month low of $29.22 and a twelve month high of $92.17. The company has a current ratio of 14.94, a quick ratio of 14.83 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $5.46 billion, a price-to-earnings ratio of 8.47 and a beta of 2.96.
Institutional investors have recently bought and sold shares of the business. Meeder Asset Management Inc. lifted its position in Nektar Therapeutics by 150.2% during the 1st quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 479 shares during the period. Quantamental Technologies LLC acquired a new stake in Nektar Therapeutics during the 1st quarter worth approximately $27,000. CSat Investment Advisory L.P. lifted its position in Nektar Therapeutics by 279.2% during the 4th quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 790 shares during the period. Laurel Wealth Advisors LLC acquired a new stake in Nektar Therapeutics during the 4th quarter worth approximately $39,000. Finally, Sandy Spring Bank acquired a new stake in Nektar Therapeutics during the 4th quarter worth approximately $59,000. 94.90% of the stock is owned by institutional investors.
NKTR has been the subject of a number of research analyst reports. BidaskClub cut Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 18th. Piper Jaffray Companies set a $100.00 target price on Nektar Therapeutics and gave the company a “buy” rating in a research report on Friday, March 1st. Mizuho reissued a “buy” rating and issued a $81.00 target price on shares of Nektar Therapeutics in a research report on Wednesday, January 23rd. ValuEngine raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 1st. Finally, Leerink Swann initiated coverage on Nektar Therapeutics in a research report on Friday, March 15th. They issued a “market perform” rating for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $69.73.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Recommended Story: Conference Calls
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.